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ABSTRACT 
Newer testing methodology allows genetics service providers to refine and personalize an at-risk 
individual’s chance to have a child with Fragile X syndrome, by determining the number and 
location of AGG insertions within the FMR1 gene.  This exploratory study aimed to better 
understand genetic counselors’ knowledge, utilization, and attitudes towards the clinical utility of 
AGG analysis for their patients.  Study investigators were under the impression counselors were 
not commonly integrating AGG analysis into their clinical practice.  The hypothesis for this 
study was that genetic counselors were reserved in their uptake of this new testing technology 
due to limited knowledge, lack of perceived importance in care, and concern for cost burden to 
patients.  To better determine reasons for limited uptake, current members of the National 
Society of Genetic Counselors, the Australasian Society of Genetic Counsellors, and the 
Association of Genetic Nurses and Counsellors were asked to participate in an online survey.  
Few survey respondents reported actually offering AGG analysis to their patients.  The majority 
desired more education before they would feel knowledgeable enough to discuss this test with 
patients.  Those with greater self-reported knowledge of AGG analysis were significantly more 
likely to discuss this testing option during counseling.  By and large, counselors perceived AGG 
analysis to be important to care and relevant to their patients.  This, in conjunction with other 
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results of the study, negates the hypothesis that lack of perceived importance in care has 
influenced low uptake.  Even in the midst of insurance concerns, there was a willingness 
amongst counselors to consider offering this testing in the future.  This study found a high level 
of desire among the participants for the establishment of formal testing guidelines by a governing 
organization, such as the National Society of Genetic Counselors or the American College of 
Medical Genetics.  Information gathered from this study will be of benefit to the genetic 
counseling profession and may impact the utilization of genetic testing methodologies in the 
future.  This research is of particular significance to the field of public health as Fragile X 
syndrome is the most common inherited cause of intellectual disability and autism. 
vi 
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1.0  INTRODUCTION 
Fragile X syndrome is the most common inherited cause of intellectual disability and autism in 
both boys and girls.  The disorder results from an expansion of a trinucleotide repeat (CGG) 
within the X-linked, Fragile X Mental Retardation-1 (FMR1) gene.  An individual with greater 
than 200 CGG repeats, can show symptoms of the syndrome.  In comparison, individuals in the 
general population commonly carry between 6 and 50 repeats (Sherman, 2000).  This disorder is 
complicated by remarkable repeat instability and risk for expansion during oogenesis and post-
zygotic mitosis (Brenda Finucane et al., 2012; Warren & Nelson, 1994).  The sex of the parent 
carrying the expanded repeat, the number of CGGs, and the number and position of AGG 
insertions influence the risk for expansion in the next generation (Yrigollen et al., 2012).  
Genetic testing has been available for decades to help predict risk for Fragile X syndrome 
in offspring.  Historically, these predictions were based solely on the number of maternal CGG 
repeats.  A newer test, that has been clinically available since 2011, enumerates AGG insertions 
within the CGG repeats.  AGG insertions have long been shown to stabilize the FMR1 gene and 
therefore help protect against repeat expansions.  By determining the number and position of 
AGG insertions, this new testing methodology can refine and personalize an at-risk individual’s 
chance to have a child with Fragile X syndrome.  Ideally, this additional information can aid 
genetic counselors in helping women to make informed decisions about family planning in 
regards to both pre- and post-conception options.  
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At present, there are no formal testing guidelines to direct genetic counselors when to 
offer AGG analysis to refine risk for expansion.  This research is an effort to better understand 
genetic counselors’ knowledge, utilization, and attitudes towards the clinical utility of AGG 
analysis for their patients.  The research will further serve to assess the desire for formal testing 
guidelines. Information gathered from this study will be of benefit to the genetic counseling 
profession and may impact the utilization of genetic testing methodologies in the future. 
1.1 HYPOTHESIS AND SPECIFIC AIMS 
1.1.1 Hypothesis 
Genetic counselors may be reserved in their uptake of new testing technology for Fragile X 
carrier status due to limited knowledge, lack of perceived importance in care, and concern for 
cost burden to their patients.  The establishment of formal testing guidelines by a governing 
organization would be a desirable resource to these healthcare professionals. 
1.1.2 Specific Aims 
Aim 1: Survey genetic counselors in the United States and abroad to characterize demographics, 
experience with counseling FMR1 intermediate and/or premutation carriers, and perceptions and 
utilization of AGG analysis. 
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Aim 2: Explore perceived barriers to offering AGG analysis by investigating associations 
between survey variables, including current knowledge of AGG analysis and its impact on 
testing perceptions and utilization.  
 
Aim 3: Ascertain genetic counselors level of desire for the establishment of formal testing 
guidelines by a governing organization. 
1.2 BACKGROUND AND SIGNIFICANCE 
1.2.1 Fragile X Syndrome 
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and 
autism in both boys and girls.  It is estimated to affect ~1 in 4,000 males and ~1 in 8,000 females 
(Crawford, Acuña, & Sherman, 2001). While females with Fragile X syndrome generally have 
milder features than males, they can also exhibit a similar range of characteristics (McConkie-
Rosell et al., 2005).  In addition, variability in both sexes can result from mosaicism either in 
DNA methylation or repeat size (Warren & Nelson, 1994). The physical, cognitive and 
behavioral phenotype is therefore best recognized as a continuum with variable expressivity. 
Physical characteristics can include long narrow face, prominent ears, prominent 
forehead or jaw, macroorchidism in male teens/adults, high arched palate, and pes planus.  
Several physical features become more visible over time.  Due to the subtlety of facial 
dysmorphism, this syndrome can easily go unrecognized based on clinical presentation alone 
(Warren & Nelson, 1994).  Individuals with FXS may also experience strabismus, recurrent otitis 
 4 
media, hyperextensible joints, epilepsy and mitral valve prolapse (B. Finucane, McConkie-
Rosell, & Cronister, 2002).   
Cognitively individuals can encounter mild to severe developmental delay, learning and 
intellectual disabilities.  Behavioral concerns can include attention deficit hyperactivity disorder 
(ADHD), hand flapping and/or biting, poor eye contact, and social anxiety.  In addition, 
individuals with FXS can have speech and language delays and often exhibit rapid, repetitive 
speech.  Many behavioral traits have significant overlap with autistic spectrum disorders, 
including difficulty with transitions and avoidance behaviors due to increased sensitivity to 
sounds, touch, crowds, certain foods and textures (B. Finucane et al., 2002).  It has been 
estimated that as many as 30% of males with FXS meet formal diagnostic criteria for autism (R. 
Hagerman et al., 2009). 
1.2.1.1 Treatment and Management 
At present, there is no cure for FXS.  Treatments and interventions are supportive in 
nature to help individuals reach their full potential.  All individuals are eligible for early 
intervention services (Crawford et al., 2001).  Other treatments include the integration of 
occupational, physical, speech and language therapies into a special education program.  In 
addition, some individuals benefit from behavioral interventions and medications to help manage 
their hyperactivity, poor attention span and/or other behavioral and emotional problems.  As each 
child and adult with FXS can have a different presentation, it is beneficial to provide tailored 
care based on the individuals strengths and weaknesses (Brenda Finucane et al., 2012). 
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1.2.2 Molecular Genetics 
Fragile X syndrome is one of several disorders caused by mutations in the Fragile X Mental 
Retardation-1 (FMR1) gene.  The FMR1 gene is located on the X-chromosome at position 
Xq27.3 and codes for the Fragile X Mental Retardation Protein (FMRP), which is necessary for 
pre- and postnatal brain development (Crawford et al., 2001).  This trinucleotide repeat disorder 
results from an expansion of CGG repeats within the FMR1 gene (Crawford et al., 2001).  It is 
now understood that CGG expansion occurs in the 5’ untranslated region of the first exon.  A 
repeat expansion of greater than 200 CGGs leads to hypermethylation of the promoter region and 
suppresses transcription (Eichler et al., 1994).  The methylated gene is therefore unable to make 
its FMRP protein product, which is normally abundant in neurons and expressed in a variety of 
other tissues (McConkie-Rosell et al., 2005). 
Fragile X syndrome is inherited as an X-linked disorder with reduced penetrance.  As 
with any X-linked disorder, a mother has a 50% chance to pass on her affected X chromosome to 
each of her children and a father will pass on his X chromosome to all of his daughters and none 
of his sons. The sex of the parent carrying the expanded repeat, the number of CGGs, and the 
number and position of AGGs influence the risk for expansion in the next generation (Yrigollen 
et al., 2012).  A 2012 study assessed the contribution of maternal age and found that it was not a 
statistically significant contributor to expansion risk (Yrigollen et al., 2012). 
Rarely, Fragile X syndrome can be the result of a point mutation or deletion of all, or a 
portion, of the FMR1 gene.  This accounts for fewer than 1% of individuals with FXS 
(McConkie-Rosell et al., 2005).  However, because sequencing of FMR1 is not routinely 
practiced this is less likely to be picked up outside of a research setting (Crawford et al., 2001). 
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1.2.2.1 History 
Prior to the discovery of the FMR1 gene, early Fragile X researchers made the 
observation that penetrance in these families appeared to increase with successive generations.  
Researchers were able to make educated hypotheses about the risk for female carriers to have an 
affected child based on their placement within the pedigree.  This was called the Sherman 
paradox (Sherman et al., 1985).  In 1991, the FMR1 gene was identified and further research 
uncovered a correlation between increasing number of CGG repeats and proclivity for disease. 
(Fu et al., 1991; Heitz, Devys, Imbert, & Kretz…, 1992). As the expanded allele is passed on 
through a family it tends to increase in size, which explains the greater number of affected 
children in later generations (Warren & Nelson, 1994).  Resolution to the Sherman paradox came 
with the recognition of the phenomenon termed anticipation, whereby the number of affected 
individuals increases in subsequent generations.   
The molecular mechanism of Fragile X provided the first evidence that not all disease-
causing mutations are stably transmitted (Orr & Zoghbi, 2007).  Interestingly, while these 
unstable trinucleotide repeats were first described in Fragile X syndrome, trinucleotide instability 
is not isolated to FXS.  Over the next three years, unstable trinucleotide repeats were observed in 
several other neurological disorders such as Huntington disease, Spinocerebellar ataxia type 1, 
Kennedy’s disease and Myotonic dystrophy.  Each of these disorders is further characterized by 
anticipatory inheritance.  The discovery of trinucleotides made a lasting impact on research 
related to mental retardation, Huntington disease, inherited ataxias and muscular dystrophy.  As 
of 2007, these expansions were known to account for at least 16 neurological conditions (Eichler 
et al., 1994; Orr & Zoghbi, 2007). 
 7 
Historically, predicting the risk of CGG repeat expansion in offspring has been of 
considerable difficulty.  This is particularly true for women with alleles in the intermediate range 
(45 to 54 repeats), which overlap the high-end of that found in the general population and the 
low end of that found in Fragile X families (Fu et al., 1991; Warren & Nelson, 1994).  This 
difficulty in predicting expansion was illuminated by studies that identified stable and unstable 
alleles of similar size.  This suggested that a feature other than repeat length must also be 
involved in stability (Eichler et al., 1994).  Other research noted that repeat size seemed to be 
more similar among siblings than among unrelated patients.  This too suggested a factor outside 
of repeat length must play a role in expansion.  These observations were particularly relevant to 
genetic counselors, as the risk to have a child with Fragile X syndrome could significantly differ 
even amongst women with the same repeat size (S. Nolin et al., 1996). 
In the mid-1990s, researchers observed AGG triplets interspersed within the CGG repeat 
tract.  It was soon hypothesized that the number and position of interrupting AGGs were 
involved in stability and their loss contributed to disease predisposition (Warren & Nelson, 
1994).  Supporting studies found that most FMR1 alleles possessed two interspersed AGG 
interruptions, whereas those shown to have zero or one had an increased likelihood of unstable 
transmissions.  A 1994 study, suggested that 34 to 37 consecutive CGGs were a threshold for 
repeat instability, with larger repeat numbers conferring a higher likelihood of expansion.  The 
presence of AGG trinucleotides suggested enhanced stability and instability was thought to result 
from their loss (Eichler et al., 1994). Follow-up studies investigated the smallest repeat lengths to 
expand to a full mutation in one generation.  They found that these alleles, containing 56 and 59 
CGGs, had zero AGG interruptions.  This served to underscore the probable role of AGG 
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interruptions in providing intergenerational repeat stability (Fernandez-Carvajal et al., 2009; 
Sarah Nolin et al., 2003). 
Researchers concluded the loss of AGG was an important mutational event in 
predisposing individuals to Fragile X syndrome (Eichler et al., 1994).  The precedence for this 
model was established for Spinocerebellar ataxia type 1, in which all disease alleles exhibit loss 
of CAT interruptions from the CAG trinucleotide repeat (Chung et al., 1993).  With other triplet 
repeat conversions in mind, later researchers proposed that the loss of AGG interruptions could 
be the result of an A to C transversion or a deletion (Eichler et al., 1994).  Furthermore, it was 
postulated that the loss of AGG interruptions resulted in an increased rate of DNA slippage 
(Zhong et al., 1996). Unfortunately, come present day the molecular basis of the “AGG effect” 
has still not been fully elucidated (Yrigollen et al., 2012). 
1.2.2.2 CGG Repeat Length 
The length of CGG repeats can be divided into four categories: stable (6 to 44), 
intermediate (45 to 54), premutation (55 to 200) and full mutation (>200).  The categorization of 
repeat lengths is somewhat arbitrary, as different studies have used varying repeat length cut-
offs.  To address these ambiguities the American College of Medical Genetics operationally 
defined these categories based on size of CGG repeat, irrespective of the presence or absence of 
AGG interruptions (Maddalena et al., 2001).  The influence of repeat size on possible clinical 
features and likelihood of expansion can be seen in Table 1. 
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Table 1. Influence of CGG Repeat Size  
Category Repeat Size Clinical Features Likelihood of Expansion 
Stable 6 to 44 None Stable 
Intermediate 45 to 54 None Small likelihood—usually only by a few repeats 
Premutation 55 to 200 
Fragile X-associated 
primary ovarian 
insufficiency; 
Fragile X-associated 
tremor/ataxia syndrome 
Unstable—may expand to 
full mutation with maternal 
transmission 
Full mutation >200 Fragile X syndrome  Unstable 
 
Stable FMR1 alleles are common among the general population and are usually 
transmitted from parent to offspring in a stable manner (Crawford et al., 2001).  Most individuals 
have thirty CGG repeats, with AGG interruptions occurring most often at positions 10 and 20 
(Sarah Nolin et al., 2003; S. Nolin et al., 1996).   
Alleles with 45 to 54 CGG repeats fall into the gray zone or intermediate range.  
Intermediate alleles show variable stability but have not been shown to expand to a full mutation 
within one generation (Fu et al., 1991).  The smallest known single-generation expansion to a 
full mutation is 56 repeats.  Interestingly in that case study, the maternal grandfather was a 
carrier of an intermediate allele with 52 repeats.  This is demonstrative of an intermediate allele 
expanding to a full mutation within two generations (Fernandez-Carvajal et al., 2009). 
Premutation alleles are considered extremely unstable in meiotic transmission and may 
expand to a full mutation in one generation.  In addition, they have been shown to be mitotically 
unstable, as mosaicism has been observed on numerous occasions (Fu et al., 1991).  Premutation 
alleles mutate virtually every time males or females pass them on.  This transmission most often 
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results in an increased CGG repeat length.  In fact, nearly all those who inherit a maternal 
premutation (98.7%) carry a larger repeat size than their mother (S. Nolin et al., 1996).  These 
premutation alleles will eventually expand to a full mutation via maternal transmission.  The risk 
for expansion has been shown to intensify with increased CGG repeat length (Sarah Nolin et al., 
2003).  For example, maternal alleles with >90 repeats almost always expand to a full mutation 
within one generation (Crawford et al., 2001). Importantly, individuals with a premutation allele 
do not typically show symptoms of FXS, though they can face unique alternate health problems 
(Warren & Nelson, 1994). 
Finally, the full mutation is defined by a combination of repeat expansion (>200 CGG 
repeats) and DNA methylation.  Remarkably, some individuals have more than 1,000 repeats. 
This massive expansion in repeats causes the FMR1 gene to become methylated inducing 
transcriptional silencing. While all males with a full mutation are affected with FXS, only 
approximately half of females show symptoms.  This reduced penetrance in females can largely 
be attributed to X-inactivation (Warren & Nelson, 1994).  Other phenotypic variability in both 
sexes can be attributed to methylation status and mosaicism (Brenda Finucane et al., 2012).  A 
study done in 1992, found ~15% of subjects with a full mutation were in fact mosaics with some 
cells containing premutation alleles (Heitz et al., 1992).  This finding is indicative of mitotic 
instability in the full mutation.  While women with a full mutation (>200 repeats) can pass on a 
full mutation to their children, paternal transmission of the full mutation is rare.  Men with a full 
mutation typically only pass on a premutation allele to their daughters.  This is theorized to be 
due to differences in the male germ line, perhaps because of selection against the full mutation in 
sperm (Crawford et al., 2001; S. Nolin et al., 1996).  
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1.2.2.3 Predicting Risk for Expansion 
In 2006, the National Society of Genetic Counselors established a task force charged with 
updating the definition of genetic counseling (National Society of Genetic Counselors' Definition 
Task et al., 2006).  This group of experts carefully constructed the below definition. 
Genetic counseling is the process of helping people understand and adapt to 
the medical, psychological and familial implications of genetic contributions 
to disease.  This process integrates the following: 
• Interpretation of family and medical histories to assess the chance of 
disease occurrence or recurrence. 
• Education about inheritance, testing, management, prevention, 
resources and research. 
• Counseling to promote informed choices and adaptation to the risk or 
condition. 
 
In alignment with this definition, it is of upmost importance for genetic counselors 
working with families at-risk to have a child with an FMR1 mutation, to provide accurate 
assessments of likelihood.  However, an accurate evaluation of occurrence or recurrence in a 
family is dependent on the technology available.  In order to promote informed choices among 
women who are weighing the risk of having a child with Fragile X syndrome, counselors need to 
continually stay informed of the benefits and limitations of new testing technology. 
In 2003, maternal CGG repeat sizes were collected in an effort to clarify the risk for 
expansion to full mutation.  The researchers were cautious in interpreting risk estimates due to 
the possible influence of ascertainment bias from including only Fragile X families.  This 
method theoretically could have excluded stable alleles in the same size category (Sarah Nolin et 
al., 2003).  In 2011, Nolin et al. confirmed that expansion risk appeared higher for women with a 
family history of FXS as compared to those without.  Through a prospective systematic analysis 
of over 1,000 prenatal samples, their group was able to refine the risks for expansion by maternal 
repeat size (Sarah Nolin et al., 2011). The risks from both studies are outlined in Table 2.   
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Table 2. Risk for Expansion to Full Mutation by Maternal Repeat Size 
 Study by Nolin et al. 2003 Study by Nolin et al. 2011 
Maternal 
Repeat Size 
% Expanding to 
Full Mutation 
No. of 
Transmissions 
% Expanding to 
Full Mutation 
No. of 
Transmissions 
55 to 59 3.7%  1/27 0% 0/86 
60 to 69 5.3%  6/113 2.5% 2/81 
70 to 79 31.1% 28/90 31.9% 15/47 
80 to 89 57.9% 81/140 73.8% 45/61 
90 to 99 80.2% 89/111 93.9% 31/33 
100 to 200 98.5% 194/197 97.9% 93/95 
 
In most regards the 2011 study seemed to corroborate the findings from 2003.  Of 
significance, the risk for expansion to a full mutation from a maternal repeat size of 55 to 59 
seemed to be substantially less than previously thought.  In addition, the updated risk for 
expansion was higher for mothers with 80 to 100 repeats (Sarah Nolin et al., 2011).  
For a time, the percentages outlined above were the most accurate numbers available to 
genetic counselors providing risk assessment.  Although researchers were aware that expansion 
was influenced by the absence of normally interspersed AGG triplets, the contribution of AGGs 
to this expansion risk was not quantified until 2012.  At that time, Yrigollen, et al. retrospectively 
analyzed 267 premutation alleles, accounting for almost 400 transmission events.  The group 
collected data on maternal CGG repeat lengths, the number and position of AGG interruptions, 
and repeat lengths in offspring.  Their results supported previous findings that AGG interruptions 
decreased the chance of expansion to a full mutation.  Yrigollen, et al. felt the results were 
significant enough to conclude “that failure to account for AGG interruptions can result in 
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profound errors in predicted risk for fragile X syndrome”.  Furthermore, their group believed 
AGG analysis was imperative to accurate assessments of risk for mothers who are premutation 
carriers (Yrigollen et al., 2012).   
Yrigollen et al. demonstrated that AGG interruptions at least partially reduced expansion 
risk for all maternal premutations below ~100 CGGs.  However, AGG interruptions seemed to 
have the greatest influence in risk prediction for alleles with 70-80 CGG repeats, as seen in 
Figure 1.  In this repeat range, difference in risk varied by ~60% depending on number of AGGs 
present.  As an example, the risk for expansion to a full mutation for a repeat length of 75 CGGs 
was 77% for alleles with no AGGs, as compared to 12% for alleles with two AGGs (Yrigollen et 
al., 2012).  
 
 
Figure 1. Predicted Risk for Expansion to Full Mutation 
*Adapted from (Yrigollen et al., 2012) 
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Another 2012 study analyzed the impact of AGG insertions on small premutation alleles 
with 45-69 CGG repeats.  Their results demonstrated the use of AGG analysis to differentiate 
small premutation alleles at the greatest risk for instability.  In particular, they observed a clear 
risk to have a child with a full mutation for women carrying alleles of greater than 54 repeats and 
lacking AGG insertions.  The authors felt the risks posed to these women warranted the option of 
prenatal diagnosis (Sarah Nolin et al., 2013). 
1.2.3 Other FMR1-Related Disorders 
It was initially suspected that carriers of the unstable premutation allele did not have phenotypic 
consequences.  Researchers theorized that because these alleles were unmethylated and 
transcriptionally active, they produced expected levels of protein product, FMRP (Sherman, 
2000).  While some premutation carriers do not have associated health problems, research has 
uncovered that many present with a spectrum of physical, cognitive, and behavioral findings.  
These can range from mild features of Fragile X syndrome, to fragile X-associated primary 
ovarian insufficiency, to fragile X-associated tremor/ataxia syndrome (McConkie-Rosell et al., 
2005).  Therefore, the identification of a proband with Fragile X syndrome can easily lead to the 
recognition of multigenerational family involvement (R. Hagerman et al., 2009). 
1.2.3.1 Fragile X-associated Primary Ovarian Insufficiency 
In 1991 researchers, such as Cronister et al., began to investigate a perceived earlier onset 
of menopause amongst heterozygous carriers.  Their study was performed prior to the 
categorization of women as pre- or full mutation carriers.  Interestingly, they found 13% (8/61) 
of non-impaired carriers had onset of menopause before the age of 40, as compared to only 5% 
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among the control group (Cronister et al., 1991).  Future studies were able to delineate pre- and 
full mutation carriers, showing women who carried the premutation were at the increased risk for 
ovarian dysfunction.  These women were at as high as a 21% (95% confidence interval: 15-27%) 
risk for cessation of menses before the age of 40.  Surprisingly, women with a full mutation were 
similar to the general population risk, 1% (Sherman, 2000).  It was unclear whether variable 
expressivity or reduced penetrance played a role for the female premutation carriers not 
experiencing early menopause.  Furthermore, age at menopause did not seem to be correlated 
with specific repeat size or X-inactivation pattern.  Studies went on to suggest that subtle 
changes in FMRP expression might influence ovarian function.  Researchers have since 
proposed that the absence of primary ovarian insufficiency in women with the full mutation 
relates to mRNA production.  Women with the premutation allele produce the transcript with a 
large repeat tract, whereas full mutation carriers exclusively produce mRNA from their normal 
allele (Sherman, 2000).   
1.2.3.2 Fragile X-associated Tremor/Ataxia Syndrome 
Fragile X-associated tremor/ataxia syndrome is another relevant FMR1-related disorder.  
This progressive neurodegenerative condition is estimated to effect ~46% of aging male and 
17% of aging female premutation carriers (Rodriguez-Revenga et al., 2009). Symptoms can 
include intention tremor, gait ataxia, peripheral neuropathy, autonomic dysfunction, brain 
atrophy and cognitive decline (P. Hagerman & Hagerman, 2004).   
1.2.3.3 Other Premutation-associated Issues 
The penetrance of premutation pathologies in Fragile X syndrome families was 
investigated in the late 2000s.  Amidst noting premature ovarian insufficiency to be present in 
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almost one-fifth (19%) of women, they also found thyroid disease and chronic muscle pain to be 
fairly common among adult women with premutation alleles (16% and 24% respectively) 
(Rodriguez-Revenga et al., 2009).  An increased frequency of autoimmune disorders, such as 
hypothyroidism and fibromyalgia, has also been observed (R. Hagerman et al., 2009; McConkie-
Rosell et al., 2005). Finally, investigators observed higher than expected rates of mental health 
issues, hypertension, tremor and neuropathy in these adult women (Brenda Finucane et al., 2012; 
P. Hagerman & Hagerman, 2004). 
1.2.4 Testing 
There have been a myriad of tests available to patients and their families both prior to and after 
the FMR1 gene discovery.  Almost all males with Fragile X syndrome, and some affected 
females, exhibit an inducible fragile site at the distal end of the X chromosome.  Prior to 1991, 
chromosome analysis for this cytogenetic marker, FRAXA, was a commonly used diagnostic test 
(Warren & Nelson, 1994). Researchers Sutherland and Jacky were at the forefront of 
investigations to describe the conditions of tissue culture needed to induce fragile sites (Hecht, 
Jacky, & Sutherland, 1982; Jacky, Beek, & Sutherland, 1983).  However, this test method was 
not able to detect carriers and often delivered inconclusive or inaccurate results (Warren & 
Nelson, 1994).  The inducible FRAXA fragile site eventually proved valuable in the 
identification of the gene itself (Crawford et al., 2001). 
Carrier testing was initiated in the late 1980’s and early 1990’s with the usage of DNA 
linkage studies.  While these studies were costly and time-consuming, they could be as high as 
99% accurate in some families.  Following the FMR1 gene discovery, testing became even more 
reliable with direct DNA analysis (B. Finucane et al., 2002).  Southern blots, in combination with 
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restriction enzymes, quickly became a popular and accepted method for DNA-based testing. This 
allowed for visualization of CGG repeat expansion and determination of methylation status for 
an individual.  This labor intensive test requires a large amount of DNA (Crawford et al., 2001).  
DNA diagnostic tests using polymerase chain reaction (PCR) are inexpensive, automated 
and fast. PCR can be performed on much smaller amounts of DNA and can typically distinguish 
alleles in the normal, intermediate, premutation and full mutation range.  Various PCR protocols 
have equally variable sizing accuracies.  Most laboratories take advantage of both Southern Blot 
and PCR to increase sensitivity to 99% for detecting affected and carrier individuals (Crawford 
et al., 2001; McConkie-Rosell et al., 2005).   
At present, Asuragen® is the only company offering AGG analysis on a clinical basis 
and has been since 2011.  This CLIA certified laboratory uses a PCR-based approach, in 
combination with capillary electrophoresis, to determine the comprehensive FMR1 genotype.  
They report both the location and number of AGG insertions within the CGG repeat tract, for 
both males and females ("Xpansion Interpreter®," 2014).  This testing is almost always 
performed as a reflex test following determination of CGG repeat length.  The clinical report 
provided by the laboratory delivers both a risk number and risk range using a 95% confidence 
interval.  These numbers can be used to predict likelihood of expansion to a full mutation upon 
transmission to offspring.  
According to a brochure published by Asuragen®, the following reasons are appropriate 
for AGG analysis, including a) known Fragile X carriers with 45-90 repeats; b) those with a 
family history of Fragile X, Fragile X-associated tremor/ ataxia syndrome, and/or Fragile X-
associated primary ovarian insufficiency; c) those with a family history of unexplained 
intellectual disability, developmental delay or autism; and d) those with a personal or family 
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history of female infertility ("Xpansion Interpreter®: The Next Step in Fragile X Testing," 
September 2013). 
1.2.4.1 Prenatal Testing 
DNA-based testing has enhanced the accuracy of prenatal testing.  For at-risk couples 
identified to carry a pre- or full mutation, prenatal diagnosis can be performed using either 
chorionic villus sampling (CVS) or amniocentesis.  Though rare, CVS results can be complicated 
by borderline methylation patterns and may need to be clarified with amniocentesis.  
Unfortunately, regardless of testing strategy, limitations abound as to predicting the clinical 
implications of a full mutation in a female fetus and/or the consequences of a premutation later in 
life.  Couples at risk to have a child with an FMR1 mutation have a variety of pre-conception 
options including gamete donation, adoption and pre-implantation genetic diagnosis to avoid the 
risk of passing on an expanded allele (Brenda Finucane et al., 2012; McConkie-Rosell et al., 
2005). 
1.2.4.2 Population Screening 
Population-based screening has been an evolving discussion in the United States.  While 
there is evidence for racial and ethnic variability, studies suggest the prevalence of premutations 
in the Caucasian general population is ~1 in 1,000 for men and between 1 in 246 and 1 in 468 for 
women.  Some groups feel this relatively high prevalence, coupled with recent technological 
advances in testing, make Fragile X syndrome amenable to screening (Crawford et al., 2001).   
Some proponents have considered offering women of reproductive age preconception 
screening to inform carriers of their genetic status and reproductive risk.  In fact, FMR1 mutation 
testing is increasingly being offered to women who express interest even without any known risk 
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factors (Brenda Finucane et al., 2012).  Others have debated the benefits and limitations of 
newborn screening, which has been investigated in research-based pilot studies (McConkie-
Rosell et al., 2007; McConkie-Rosell et al., 2005).  In addition, there have been numerous 
discussions about the potential use of FMR1 mutation testing as a diagnostic tool for women 
with ovarian dysfunction.  This type of testing could have a relatively high diagnostic yield, as 
approximately 13.8% of idiopathic familial premature ovarian failure can be uniquely attributed 
to the premutation allele (Sherman, 2000). 
The common detection of intermediate alleles in screening for Fragile X carriers is of 
particular concern.  According to a 1996 study, ~4.8% of males and 9.5% of females randomly 
selected from the general population will have an allele size of 40 to 60 CGGs.  These 
intermediate alleles are particularly important to consider as they present difficult issues for 
genetic counseling (S. Nolin et al., 1996).  When CGG repeats in this range are detected in the 
general population they become particularly difficult to interpret (McConkie-Rosell et al., 2005). 
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2.0  MATERIALS AND METHODS 
This thesis project was reviewed by the University of Pittsburgh’s Institutional Review Board 
and was determined to meet criteria for exemption (Appendix A). 
2.1 PARTICIPANTS 
This exploratory study sought the opinion of genetic counselors both nationally and 
internationally.  Current members of the National Society of Genetic Counselors (NSGC), the 
Australasian Society of Genetic Counsellors (ASGC), and the Association of Genetic Nurses and 
Counsellors (AGNC) were invited to participate.  The NSGC is comprised of approximately 
3,000 members practicing across the United States and into Canada.  The ASGC is made up of 
271 members practicing across Australia and New Zealand.  The AGNC has approximately 300 
genetic professionals practicing in the United Kingdom. 
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2.2 INSTRUMENTATION 
2.2.1 Recruitment E-mail 
E-mails inviting genetic counselors to participate in an online survey were drafted for members 
of the NSGC, ASGC, and AGNC.  A copy of each of these e-mails can be seen in Appendix 
B.2.1, Appendix B.2.2, and Appendix B.2.3, respectively. These e-mails served as an 
introduction for genetic counselors to the project and provided a link to access the survey on the 
Internet.  An e-mail was sent out to all members of the NSGC on October 9, 2013 through an E-
mail blast system called Constant Contact.  A reminder e-mail went out to the same group on 
October 23, 2013.  Members of the ASGC were emailed by their secretariat through a listserv, on 
November 24, 2013.  Finally, the AGNC Vice-Chair emailed their members on October 23, 
2013.  In addition, several genetic counselors interested in this thesis project took the liberty of 
forwarding their own reminder e-mails to colleagues. 
2.2.2 Recruitment Brochure 
In order to help generate interest in this project, several copies of a recruitment brochure were 
distributed and posted at the NSGC 32nd Annual Education Conference held October 9-12, 
2013, at the Anaheim Convention Center in Anaheim, California.  This brochure was designed to 
generate interest in the project and provide a link to access the survey on the Internet.  In 
addition, this served as a reminder for NSGC members who received the invitation e-mail on 
October 9th but had not yet completed the survey.  A copy of this recruitment brochure can be 
seen in Appendix B.1. 
 22 
2.2.3 Survey Design 
The earliest draft of this survey was the collaborative effort of genetic counselors, Brenda 
Finucane, MS, LGC from Geisinger Health System and Amy Cronister, MS from Integrated 
Genetics.  A copy of this survey’s first draft from June of 2013 can be seen in Appendix C.  This 
early draft was then circulated for feedback to four other well-respected genetic counselors with 
expertise in Fragile X including, Liane J. Abrams, MS, LGC from the National Fragile X 
Foundation, Alison D. Archibald, PhD, GDipGenetCouns from the Victorian Clinical Genetics 
Services, Robin L. Bennett, MS, CGC, D. Sc. Hon. from the University of Washington Medical 
Center, and Allyn McConkie-Rosell, PhD, CGC from Duke University Medical Center.   
In July of 2013, the author was recruited as a genetic counseling graduate student to bring 
this research project to fruition as part of this thesis project.  Together with the genetic 
counselors mentioned above, the survey was carefully evaluated several times as questions were 
added, removed and restructured.  It was eventually reformatted and reorganized to create a 
seemingly more efficient structure.  Statistician, Daniel Normolle, PhD, also evaluated this 
survey.  Dr. Normolle helped to ensure the questions were unbiased and constructed in such a 
way as to be most likely to achieve statistical significance.  The final version of the survey can 
be seen in Appendix D.  
The survey introduction served to inform participants that the purpose of this research 
was to explore genetic counselors’ perceptions and utilization of AGG analysis to refine the risk 
of expansion in the FMR1 gene for their patients.  There was minimal risk involved in the study, 
as all results generated through the electronic survey would be collected anonymously.  
However, given the nature of the topic, it was possible some questions could have caused 
distress as some individuals could have felt uncomfortable thinking about the ethical 
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implications of deciding whether or not to offer AGG testing to patients.  It was stressed that 
participation in this anonymous survey was voluntary and individuals had the option to exit out 
of the survey at any time.   There were no costs to participating nor were there direct benefits. 
The introduction highlighted that information gathered from this study would be of benefit to the 
genetic counseling profession and could impact the utilization of genetic testing methodologies 
in the future.  Any questions were to be targeted to the primary investigator, LHB. 
Participants were asked up to twenty-one questions.  Demographic questions were used 
to assess factors such as, how long individuals had been in practice, in what specialty area they 
focused, whether or not they counseled patients, and if they had ever counseled patients with an 
FMR1 intermediate or premutation allele.  Additional questions were structured to gauge current 
knowledge level of AGG analysis and document how this education was obtained.  Further 
questions sought to tease apart why genetic counselors were or were not offering AGG analysis 
and for whom.  The final portion of the survey was designed to capture genetic counselors’ level 
of desire for the establishment of formal testing guidelines. 
2.3 PROCEDURES 
2.3.1 Survey Distribution 
For ease of distribution and data collection, the finalized survey was made available 
electronically through SurveyMonkey®.  The electronic version of the survey differed only from 
that found in Appendix D due to its incorporation of skip logic.  Skip logic helped streamline 
questions so that participants were automatically directed to the next appropriate question. 
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2.3.2 Results Collection 
Responses were collected and analysis was initiated using features of SurveyMonkey®. The 
analysis section of the website displayed a full summary of all questions and responses, complete 
with charts and tables.  The data could be displayed in a variety of other chart types as well. 
Analysis tools on this website further allowed the researchers to filter by question and answer as 
well as to compare questions side-by-side in a process known as cross tabulation. Finally, this 
website allowed administrators to export all response data into both Microsoft Excel® and IBM 
SPSS Statistics® for more in depth analysis. 
2.4 STATISTICAL ANALYSIS 
Statistical analysis of the quantitative and qualitative data was performed under the guidance of a 
statistician at the University of Pittsburgh.  Data was exported from SurveyMonkey® into both 
Microsoft Excel® and IBM SPSS Statistics®.  Much of the descriptive statistics were performed 
using the SurveyMonkey® analysis tools.  These tools quickly tabulated answers and allowed 
the investigators to filter by question and answer as well as to compare questions side-by-side in 
a process known as cross tabulation.  In IBM SPSS Statistics®, Fisher’s exact test was 
performed on two-by-two tables to check for statistical significance for numerous comparisons.  
Of note, there were a few questions that asked participants to “fill-in-the-blank” with a number.  
Some individuals wrote estimations such as “1 to 2” years in practice or “more than 20” patients 
counseled.  For a conservative approach to our statistical analysis these values were either 
recorded as the median of their answer or the lowest value (1.5 and 20, respectively). 
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3.0  RESULTS 
3.1 NSGC RESPONDENT STATISTICS 
3.1.1 Demographics 
Two thousand nine hundred and thirty-two NSGC members were successfully e-mailed to 
participate in this research study. Five hundred and sixty-nine individuals opened the email, 
which accounts for 19.4% of all individuals that received the email.  As a comparison, according 
to the NSGC Membership Associate most student research surveys have open rates between 13 
and 22%.  In total, three hundred and ninety members (13.3%) agreed to participate.   
Of the 390 NSGC respondents, almost all (94.9%; n=370) reported working primarily in 
the United States.  The rest worked in Canada (4.9%; n=19) and one counselor reported working 
in Australia.  Approximately half (55.1%; n=215) of the counselors surveyed had been practicing 
for five years or less, as can be seen in Figure 2.  The mean years of practice was 8.11 years (SD 
± 8.69; range 0 to 39 years; n=390).  The median was 4 years of practice.  
The survey further elicited which specialty area(s) counselors practiced in.  The majority 
(60.3%; n=235) of survey respondents reported specializing in prenatal genetics.  Some of these 
counselors reported specializing in additional areas of genetics as well.  Figure 3 shows the 
distribution of specialty area(s) by respondents. In the “Other” category, respondents reported 
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myriad specialties including neurology, ophthalmology, cardiovascular disease, metabolic 
disease, and infertility to name a few.  Of the 44 counselors who marked “Other”, most of them 
(59.1%; n=26) also identified with at least one of the provided answer choices. 
 
  
Figure 2. NSGC—Years in Practice 
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Figure 3. NSGC—Specialty Area(s)  
*Respondents (n=390) were able to select multiple specialty areas. 
3.1.2 Knowledge of AGG Analysis 
In order to assess knowledge levels, counselors (n=386) were asked how familiar they were with 
the notion of analyzing AGG interruptions in women with an FMR1 intermediate or premutation 
allele.  The counselors were asked to rate their familiarity on a scale of 1 to 4, with 1 being not at 
all knowledgeable and 4 being very knowledgeable.  Most counselors (81.9%; n=316) reported 
at least some degree of knowledge.  However, only 11.7% of counselors (n=45) considered 
themselves very knowledgeable, as can be seen in Figure 4.   
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Figure 4. NSGC—Familiarity with Analyzing AGG Interruptions 
*Respondents (n=386) were asked to rate their familiarity on a scale from not at all knowledgeable (1) to very 
knowledgeable (4). 
 
Amongst the counselors with at least some degree of knowledge (rating themselves 2, 3 
or 4), education about AGG analysis was obtained in a wide array of methods.  Out of the 313 
counselors answering this question, all with at least some degree of knowledge, almost half 
(47.9%; n=150) reported reading peer-reviewed articles on the studies performed to date.  Many 
also reported attending lectures/presentations on AGG analysis and/or reading promotional 
materials from a company or institution that performs the testing.  In response to this question, a 
few individuals (n=33) added additional comments about where they obtained their knowledge.  
The most often cited additional sources were discussions with colleagues, reading 
GeneReviews™, in genetic counseling training programs, and while attending NSGC’s Annual 
Education Conference.  The breakdown of education method can be found in Figure 5. 
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Figure 5. NSGC—AGG Analysis Education Method 
*Respondents (n=313) were able to select multiple methods. 
3.1.3 FMR1 Patient Experience 
Of the 390 respondents, most (92%; n=360) reported that they counsel patients.  Further, the 
majority of counselors taking part in this survey (79.0%; n=308) have counseled a patient with 
an FMR1 intermediate or premutation allele.  Polling these 308 individuals, they have on average 
each counseled ~6.4 patients with an FMR1 intermediate or premutation allele over the past 3 
years (SD ± 11.6; range 0 to 100). The median number of patients counseled with an FMR1 
intermediate or premutation allele over the past 3 years was 3.  The distribution of FMR1 
patients counseled over the past 3 years is shown in Figure 6. 
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 Figure 6. NSGC—FMR1 Patient Experience 
 
Counselors were further asked how often they discuss the role of AGG analysis when 
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not counsel patients for this indication.  Of the remaining 256 counselors, the majority (58.2%; 
n=149) “never” discussed the role of AGG analysis, while only 13.3% (n=34) reported “always” 
discussing AGG analysis.  Interestingly, counselors who considered themselves to be more 
knowledgeable about AGG analysis were more likely to discuss this topic during counseling (p-
value = <0.0001), as can be seen in Figure 7 and Table 3.   
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Figure 7. NSGC—Frequency of Discussing AGG Analysis Based on Familiarity 
*Respondents (n=256) previously rated their familiarity with AGG analysis from not at all knowledgeable (1) to 
very knowledgeable (4), as can be seen in Figure 4. 
 
Table 3. NSGC—Frequency of Discussing AGG Analysis Based on Familiarity 
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A large percentage of counselors (79.3%; n=284) have never offered AGG testing to 
patients.  For those who have offered AGG testing (20.7%; n=74), most cited reasons such as 
assisting pregnant patients in making decisions regarding prenatal diagnosis and/or assisting 
patients in making decisions about family planning.  Only one counselor reported offering testing 
“as part of a research study”, while a small handful mentioned “standard of care” or by “patient 
request”, as can be seen in Figure 8.   
 
 
Figure 8. NSGC—Indications for Offering AGG Testing 
*Respondents (n=74) were able to select multiple indications. 
 
In order to extrapolate patient demand, counselors were asked if patients had ever asked 
about additional testing (such as AGG analysis) to help refine their risk for expansion in the 
FMR1 gene.  Out of the 383 respondents, only 21 counselors (5.48%) reported patients asking 
about their additional testing options.  Not surprisingly, these 21 counselors reported seeing a 
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greater number of patients than other counselors taking this survey.  Polling these 21 individuals, 
they each counseled ~18.6 patients with an FMR1 intermediate or premutation allele over the 
past 3 years (SD ± 24.0; range 0 to 100).  This is compared to an average of ~6.4 patients for all 
survey respondents. 
3.1.4 Barriers to Offering/Ordering AGG Testing 
Counselors were asked to answer a series of true/false questions in order to assess their perceived 
barriers (if any) to offering/ordering AGG testing (total n=350).  While most counselors (90.9%; 
n=318) felt testing was relevant for their patients with an FMR1 intermediate or premutation 
allele, a majority (67.7%; n=237) desired more education before they would feel knowledgeable 
enough to discuss this with their patients.  An equally large percentage of counselors (66.3%; 
n=232) were concerned about insurance coverage and/or the additional cost this testing would 
add for their patient.  A smaller proportion of counselors (40.3%; n=141) reported either not 
knowing this testing was available or not knowing how to go about requesting it.  Finally, one-
third of counselors (33.1%; n=116) felt information gained from AGG analysis added further 
complexity to FMR1 genetic counseling without actually changing patient decision making, as 
can be seen in Figure 9. 
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 Figure 9. NSGC—Perceived Barriers to Offering/Ordering AGG Testing  
 
The above question was further stratified to determine the impact of AGG knowledge on 
each of the perceived barriers.  As anticipated, counselors who considered themselves less 
knowledgeable about AGG analysis were more likely to select “I need more education before I 
would feel knowledgeable enough to discuss this with my patients” and “I didn’t know this 
testing was available and/or didn’t know how to request testing”, as can be seen in Figure 10 and 
Tables 4-5.  Counselors’ level of knowledge was not a significant predictor for concerns 
regarding insurance, complexity, or irrelevance, as can be seen in Figure 11 and in Appendix E, 
Tables 16-18. 
0! 50! 100! 150! 200! 250! 300! 350!
I feel this testing is not relevant for my patients 
with an FMR1 intermediate or premutation 
allele!
I feel this information adds further complexity 
to FMR1 genetic counseling without actually 
changing patient decision making!
I didn’t know this testing was available and/or 
didn’t know how to request testing!
I am concerned about insurance coverage and/
or the additional cost this testing would add for 
my patient!
I need more education before I would feel 
knowledgeable enough to discuss this with my 
patients!
# of Counselors!
Perceived Barriers to Offering/Ordering 
AGG Testing!
TRUE!
FALSE!
 35 
 
Figure 10. NSGC—Perceived Barriers Based on Familiarity I 
*Respondents (n=350) previously rated their familiarity with AGG analysis from not at all knowledgeable (1) to 
very knowledgeable (4), as can be seen in Figure 4. 
 
Table 4. NSGC—Perceived Barriers Based on Familiarity I: Education 
I need more education before I would feel knowledgeable 
enough to discuss this with my patients 
 TRUE FALSE 
Knowledge Level 
1 or 2 179 14 
Knowledge Level 
3 or 4 58 99 
One-tailed Fisher’s exact test: p-value = <0.0001 
 
Table 5. NSGC—Perceived Barriers Based on Familiarity I: Awareness 
I didn’t know this testing was available and/or didn’t 
know how to request testing 
 TRUE FALSE 
Knowledge Level 
1 or 2 117 76 
Knowledge Level 
3 or 4 24 133 
One-tailed Fisher’s exact test: p-value = <0.0001 
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 Figure 11. NSGC—Perceived Barriers Based on Familiarity II  
*Respondents (n=350) previously rated their familiarity with AGG analysis from not at all knowledgeable (1) to 
very knowledgeable (4), as can be seen in Figure 4. 
 
Perceived barriers to offering/ordering AGG testing were again stratified to determine if 
perceptions differed among those who have offered AGG testing in the past as compared to those 
who have not.  As anticipated, counselors who have offered testing in the past were less likely to 
select “I need more education before I would feel knowledgeable enough to discuss this with my 
patients” and “I didn’t know this testing was available and/or didn’t know how to request 
testing”, as can be seen in Tables 6-7.  Counselors past use of AGG testing was not a significant 
predictor for concerns regarding insurance, complexity, or irrelevance, as can be seen in 
Appendix E, Tables 19-21.  
 
0%!
20%!
40%!
60%!
80%!
100%!
1! 2! 3! 4!
Familiarity with AGG Analysis*!
Perceived Barriers Based on Familiarity II!
 I am concerned about 
insurance coverage and/or 
the additional cost this 
testing would add for my 
patient!
 I feel this information adds 
further complexity to FMR1 
genetic counseling without 
actually changing patient 
decision making !
 I feel this testing is not 
relevant for my patients with 
an FMR1 intermediate or 
premutation allele!
 37 
Table 6. NSGC—Perceived Barriers Based on Past Use: Education 
I need more education before I would feel knowledgeable 
enough to discuss this with my patients 
 TRUE FALSE 
Have offered AGG analysis to 
patients in the past 8 60 
Have NOT offered AGG 
analysis to patients in the past 229 53 
One-tailed Fisher’s exact test: p-value = <0.0001 
 
Table 7. NSGC—Perceived Barriers Based on Past Use: Awareness 
I didn’t know this testing was available and/or didn’t 
know how to request testing 
 TRUE FALSE 
Have offered AGG analysis to 
patients in the past 1 67 
Have NOT offered AGG 
analysis to patients in the past 140 142 
One-tailed Fisher’s exact test: p-value = <0.0001 
3.1.5 Future Use of AGG Analysis 
The majority of counselors (76.8%; n=275) reported being “more likely” to utilize AGG analysis 
in the presence of a family history consistent with possible Fragile X syndrome, Fragile X-
associated Tremor/Ataxia syndrome, or Fragile X-associated Primary Ovarian Insufficiency.  
Conversely, the remainder of counselors (23.2%; n=83) said they were “less likely” to utilize this 
testing methodology in the presence of those family histories. 
Counselors were further asked if there were certain CGG repeat ranges that would make 
them more likely to discuss the option of AGG testing in the future. Respondents were able to 
mark all repeat ranges that applied.  Sixty-seven counselors (18.8%; total n=357) did not plan to 
discuss this testing with their patients.  Of the remaining 290 counselors who answered with 
 38 
specific repeat ranges, about half (45.9%; n=133) would discuss AGG testing with someone with 
an intermediate allele (45-54 CGG repeats).  Furthermore, over 65% of counselors would discuss 
AGG testing with a premutation allele carrier with 55-69 CGG repeats.  In addition, the majority 
of counselors (59.7%; n=173) would discuss this testing option with individuals with 70 or 
higher CGG repeats, as can be seen in Figure 12.  Interestingly, there were 55 counselors 
(20.0%) who selected all CGG repeat ranges (from an intermediate allele with 45 CGG repeats 
up to a premutation allele with 70 or more CGG repeats).  This could be implying they would 
discuss AGG testing with an FMR1 carrier regardless of repeat length.  Counselors with greater 
knowledge of AGG analysis were significantly more likely to discuss this additional testing with 
a premutation allele carrier with 60-69 CGG repeats, as can be seen in Tables 8-9.  Knowledge 
did not seem to influence the likelihood of discussion for other repeat ranges, as can be seen in 
Appendix E, Tables 22-24. 
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Figure 12. NSGC—CGG Repeat Ranges Most Likely to Warrant AGG Discussion 
*Respondents (n=290) were able to select all repeat ranges that applied.  Counselors not planning to discuss this 
testing with their patients were excluded from this analysis. 
 
Table 8. NSGC—AGG Discussion Based on Familiarity: 60-64 repeats 
A premutation with 60-64 CGG repeats 
 Yes No Knowledge Level 
1 or 2 95 51 
Knowledge Level 
3 or 4 122 23 
Two-tailed Fisher’s exact test: p-value = 0.0002 
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Table 9. NSGC—AGG Discussion Based on Familiarity: 65-69 repeats 
A premutation with 65-69 CGG repeats 
 Yes No Knowledge Level 
1 or 2 87 59 
Knowledge Level 
3 or 4 112 33 
Two-tailed Fisher’s exact test: p-value = 0.002 
 
Another portion of the survey was designed to capture whether or not counselors planned 
to use AGG analysis differently in the future.  While only 19.0% (n=68) of respondents report 
offering AGG analysis to patients in the past, the vast majority of counselors surveyed (86.9%; 
n=311) say they would consider offering AGG analysis in the future.  Interestingly, one 
individual who reported offering the testing in the past does not plan to offer this testing again in 
the future.  Furthermore, another 12.9% (n=46) have not offered AGG analysis to patients in the 
past and do not plan to offer this testing in the future.  This breakdown can be seen in Table 10. 
 
Table 10. NSGC—Counselors Past and Future Use of AGG Analysis 
Counselors Past and Future Use of AGG Analysis 
 
Would consider 
offering in the future 
Do NOT plan to offer 
this testing in the future 
Have offered AGG analysis to 
patients in the past 68 1 
Have NOT offered AGG 
analysis to patients in the past 243 46 
Two-tailed Fisher’s exact test: p-value = 0.001 
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3.1.6 Establishment of Formal Guidelines 
There was a divide amongst genetic counselors participating in this survey, with just under half 
(44.5%; n=155) believing that informing patients about the option of AGG analysis should be the 
standard of care for genetics service providers.  Counselors rating themselves with a higher level 
of knowledge about AGG analysis were more likely to believe informing patients should be the 
standard of care, as can be seen in Table 11. 
 
Table 11. NSGC—Standard of Care 
Should informing patients about the option of AGG 
analysis be the standard of care for genetics service 
providers? 
 Yes No 
Knowledge Level 
1 or 2 67 124 
Knowledge Level 
3 or 4 88 69 
Two-tailed Fisher’s exact test: p-value = <0.0001 
 
A strong majority of counselors (90.2%; n=314) felt formal guidelines should be 
established for the purpose of identifying who should be offered AGG analysis.  Amongst these 
individuals, many believed either the National Society of Genetic Counselors or the American 
College of Medical Genetics should be the organization responsible for establishing these 
guidelines.  A more detailed breakdown of organizational preferences can be seen in Figure 13. 
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Figure 13. NSGC—Organizational Preferences for Establishment of Formal Guidelines 
*Respondents (n=313) were able to select multiple organizations. 
3.2 INTERNATIONAL RESPONDENT STATISTICS 
3.2.1 Demographics 
Two hundred and seventy-one ASGC members and approximately three hundred members of 
AGNC were e-mailed to participate in this research study.  Of these, sixteen ASGC members 
(6%) and twelve AGNC members (4%) took part in the survey.  Of the AGNC respondents, one 
was a genetic nurse and the rest were genetic counselors.  The majority of respondents (64.3%; 
n=18) had been practicing for five or more years.  The mean years of practice was 8.09 years 
(SD ± 7.04; range 0.5 to 30 years; n=28).  The median was 7 years of practice. 
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The survey further elicited which specialty area(s) counselors practiced in.  A majority 
(67.9%; n=19) of survey respondents reported specializing in prenatal genetics. Many of these 
individuals reported specializing in additional areas of genetics as well.  Interestingly, the bulk of 
counselors reported specializing in adult genetics (78.6%; n=22).  Figure 14 shows the 
distribution of specialty area(s) respondents. In the “Other” category, respondents reported 
specializing in areas such as X-linked disorders, pre-implantation genetic diagnosis, and learning 
disabilities.  Of the seven counselors who marked “Other”, most of them (71.4%; n=5) also 
identified with at least one of the provided answer choices. 
 
 
Figure 14. International—Specialty Area(s)  
*Respondents (n=28) were able to select multiple specialty areas. 
0! 4! 8! 12! 16! 20! 24!
Other!
Research/ Laboratory!
Pediatrics!
Cancer!
Prenatal!
Adult Genetics!
# of Counselors!
Specialty Area(s)!
 44 
3.2.2 Knowledge of AGG Analysis 
In order to assess knowledge levels, international counselors (n=27) were asked how familiar 
they were with the notion of analyzing AGG interruptions in women with an FMR1 intermediate 
or premutation allele.  The counselors rated themselves on a scale of 1 to 4, with 1 being not at 
all knowledgeable and 4 being very knowledgeable. Only 11.1% of counselors (n=3) considered 
themselves very knowledgeable, whereas most counselors (74.1%; n=20) reported themselves as 
not at all knowledgeable, as can be seen in Figure 15.  International respondents were less 
knowledgeable about AGG analysis than NSGC respondents, as can be seen in Table 12.  
Amongst the counselors with at least some degree of knowledge, education about AGG analysis 
was obtained by reading peer-reviewed articles on the studies performed to date, attending 
lectures/presentations on AGG analysis and/or discussing it with either a company that performs 
the testing or their own local laboratory.   
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Figure 15. International—Familiarity with Analyzing AGG Interruptions 
*Respondents (n=27) rated their familiarity from not at all knowledgeable (1) to very knowledgeable (4). 
 
Table 12. Differing Familiarity for International vs. NSGC Respondents 
Familiarity with Analyzing AGG Interruptions 
 International NSGC 
Knowledge Level 
1 or 2 22 221 
Knowledge Level 
3 or 4 5 165 
One-tailed Fisher’s exact test: p-value = 0.009 
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3.2.3 FMR1 Patient Experience 
Of the 28 international respondents, all reported that they counsel patients.  Further, the majority 
of counselors taking part in this survey (89.3%; n=25) have counseled a patient with an FMR1 
intermediate or premutation allele.  Polling these 25 individuals, they have on average each 
counseled ~5.7 patients with an FMR1 intermediate or premutation allele over the past 3 years 
(SD ± 6.3; range 0 to 20). The median number of patients counseled with an FMR1 intermediate 
or premutation allele over the past 3 years was 3.  The distribution of FMR1 patients counseled 
over the past 3 years is shown in Figure 16. 
 
 
Figure 16. International—FMR1 Patient Experience  
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likely because they do not counsel patients for this indication.  Of the remaining 21 counselors, 
the majority (81.0%; n=17) “never” discussed the role of AGG analysis.  Very few (19.0%; n=4) 
report discussing the role of AGG analysis “occasionally” or “often”, as can be seen in Figure 
17.  No one selected “always”.  Regardless of whether or not counselors chose to discuss AGG 
analysis in session, none of them (n=23) had offered clinical AGG testing and only two 
counselors (8.7%) had offered AGG testing as part of a research study.  
 
 
Figure 17. International—Frequency of Discussing AGG Analysis During Counseling 
 
In order to extrapolate patient demand, counselors were asked if patients had ever asked 
about additional testing (such as AGG analysis) to help refine their risk for expansion in the 
FMR1 gene.  Out of the 27 respondents, only 1 counselor (3.7%) reported patients asking about 
their additional testing options. 
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3.2.4 Barriers to Offering/Ordering AGG Testing 
International counselors were asked to answer a series of true/false questions in order to assess 
their perceived barriers (if any) to offering/ordering AGG testing (total n=23). The majority of 
counselors (87.0%; n=20) either didn’t know this testing was available or didn’t know how to 
request it.  In addition, the majority of respondents (82.6%; n=19) desired more education before 
they would feel knowledgeable enough to discuss this with their patients.  Most counselors did 
not report insurance concerns, complexity, or irrelevance as obstacles preventing them from 
offering/ordering AGG testing, as can be seen in Figure 18. 
 
 
Figure 18. International—Perceived Barriers to Offering/Ordering AGG Testing 
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Perceived barriers to offering/ordering AGG testing were stratified to determine if 
perceptions differed among international versus NSGC respondents.  International counselors 
were significantly more likely to select “I didn’t know this testing was available and/or didn’t 
know how to request testing”, as can be seen in Table 13.  In addition, international counselors 
were statistically less likely to mark down concerns about insurance coverage, as can be seen in 
Table 14.  Counselors need for education, concerns about complexity and feelings of irrelevance 
were not significantly influenced by affiliation with the NSGC or an international organization, 
as can be seen in Appendix E, Tables 25-27. 
 
Table 13. Perceived Barriers for International vs. NSGC Respondents: Awareness 
I didn’t know this testing was available and/or didn’t 
know how to request testing 
 TRUE FALSE 
International 20 3 
NSGC 141 209 
One-tailed Fisher’s exact test: p-value = <0.0001 
 
Table 14. Perceived Barriers for International vs. NSGC Respondents: Insurance 
I am concerned about insurance coverage and/or the 
additional cost this testing would add for my patient 
 TRUE FALSE 
International 2 21 
NSGC 232 118 
Two-tailed Fisher’s exact test: p-value = <0.0001 
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3.2.5 Future Use of AGG Analysis 
The majority of counselors (73.9%; n=17) reported being “more likely” to utilize AGG analysis 
in the presence of family history consistent with possible Fragile X syndrome, Fragile X-
associated Tremor/Ataxia syndrome, or Fragile X-associated Primary Ovarian Insufficiency.  
Conversely, the remainder of counselors (26.1%; n=6) said they were “less likely” to utilize this 
testing methodology in the presence of those family histories. 
International respondents were further asked if there were certain CGG repeat ranges that 
would make them more likely to discuss the option of AGG testing in the future.  However, this 
data was not analyzed because the majority of international respondents had previously rated 
themselves as not at all knowledgeable about analyzing AGG interruptions.  Therefore the given 
answers were largely guesses. 
Another portion of the survey was designed to capture whether or not counselors planned 
to use AGG analysis differently in the future.  The majority of counselors surveyed (91.3%; 
n=21) say they would consider offering AGG analysis in the future.  Two counselors (2.9%; 
n=46) who have not offered AGG analysis to patients in the past shared they do not plan to offer 
this testing in the future.  This breakdown can be seen in Table 15. 
 
Table 15. International—Counselors Past and Future Use of AGG Analysis 
Counselors Past and Future Use of AGG Analysis 
 
Would consider 
offering in the future 
Do NOT plan to offer 
this testing in the future 
Have offered AGG analysis to 
patients in the past 1 0 
Have NOT offered AGG 
analysis to patients in the past 20 2 
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3.2.6 Establishment of Formal Guidelines 
The majority of international counselors (72.7%; n=16) did not believe informing patients about 
the option of AGG analysis should be the standard of care for genetics service providers.  This 
approached but did not reach statistical significance as compared to NSGC respondents 
(Appendix E, Table 28).  However, a strong majority (90.9%; n=20) felt formal guidelines 
should be established for the purpose of identifying who should be offered AGG analysis.  While 
some respondents thought either the American College of Medical Genetics or the National 
Society of Genetic Counselors should be the organization responsible for establishing these 
guidelines, others specified organizations such as the Human Genetics Society of Australasia, the 
British Society for Genetic Medicine, and the Association of Genetic Nurses and Counsellors.  A 
more detailed breakdown of organizational preferences can be seen in Figure 19. 
 
 
Figure 19. International—Organizational Preferences for Establishment of Formal Guidelines 
*Respondents (n=20) were able to select multiple organizations. 
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4.0  DISCUSSION 
This research was an effort to better understand genetic counselors’ knowledge, utilization, and 
attitudes towards the clinical utility of AGG analysis for their patients.  The research further 
served to assess the desire for formal testing guidelines. Information gathered from this study 
will be of benefit to the genetic counseling profession and may impact the utilization of genetic 
testing methodologies in the future. 
4.1 DISCUSSION OF NSGC RESULTS 
4.1.1 Demographics 
Of the two thousand nine hundred and thirty-two NSGC members invited to participate in this 
survey, three hundred and ninety members (13%) agreed to participate.  Almost all (95%) 
reported working primarily in the United States.  The rest worked in Canada and one counselor 
reported working in Australia.  Experience ranged from 0 to 39 years, with an average of 8 years.  
Approximately half of the counselors surveyed had been practicing for five years or less.  
The majority (60%) of survey respondents reported specializing in prenatal genetics.  
This can be compared to the 2012 NSGC Professional Status Survey, which documented 29% of 
genetic counselors in prenatal genetics.  It would seem that genetic counselors practicing in this 
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specialty were more likely to take an interest in this survey.  Pediatric genetics was the next most 
common specialty area.  Not surprisingly, a few individuals mentioned their involvement in 
infertility, which has been a growing area for Fragile X carrier testing. 
4.1.2 Knowledge of AGG Analysis 
Most counselors (82%) reported at least some degree of knowledge about AGG analysis.  
However, only 12% of counselors considered themselves very knowledgeable.  Amongst 
counselors with at least some knowledge of AGG analysis, education was obtained in a wide 
array of methods.  Almost half of these counselors reported reading peer-reviewed articles on the 
studies performed to date.  Many also reported attending lectures/presentations on AGG analysis 
and/or reading promotional materials from a company or institution that performs the testing.  A 
minority of counselors either discussed this testing with a company or institution that performs it, 
or viewed or participated in a webinar.  A few individuals added additional comments citing 
discussions with colleagues, reading GeneReviews™, in genetic counseling training programs, 
and while attending NSGC’s Annual Education Conference. 
4.1.3 FMR1 Patient Experience 
Almost all the genetic counselors surveyed counsel patients (92%).  This can be compared to the 
2012 NSGC Professional Status Survey, which documented 77% of respondents counseling 
patients as a regular part of their jobs.  It would seem that those counseling patients were more 
likely to take an interest in this survey.  Further, the majority (79%) have counseled a patient 
with an FMR1 intermediate or premutation allele.  Polling these individuals, they have on 
average each counseled ~6.4 patients with an FMR1 intermediate or premutation allele over the 
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past 3 years, ranging from 0 to “more than I can count, several 100 maybe more”. The median 
number of patients counseled with an FMR1 intermediate or premutation allele over the past 3 
years was 3. 
Counselors were further asked how often they discuss the role of AGG analysis when 
counseling patients with an FMR1 intermediate or premutation allele.  About a quarter of the 
respondents felt this question was not applicable to them, likely because they do not counsel 
patients for this indication.  Of the remaining counselors, the majority (58%) “never” discussed 
the role of AGG analysis, while only 13% reported “always” discussing AGG analysis.  Most 
interesting was that counselors who considered themselves to be more knowledgeable about 
AGG analysis were significantly more likely to discuss this topic during counseling.  This lends 
insight to the fact that genetic counselors who were knowledgeable about this testing option 
perceived it to be important to care.  One counselor who ran a Fragile X family support group for 
almost a decade, commented in the survey that if he/she was still working with patients, he/she 
would want to “make all patients with an intermediate allele or higher aware of this testing”.  
A minority of counselors (21%) have actually offered AGG testing to their patients.  For 
these individuals, most cited reasons such as assisting pregnant patients in making decisions 
regarding prenatal diagnosis and/or assisting patients in making decisions about family planning.  
Only one counselor reported offering testing “as part of a research study” and a small handful 
mentioned “standard of care” or by “patient request”.  Some counselors left comments such as, 
“My patients have liked the opportunity to get a clear risk about the likelihood of having a future 
child with Fragile X” and “AGG analysis often plays a role in a patient's decision to undergo 
invasive testing.  It has the potential to clarify the risk for expansion in pregnancies and future 
pregnancies.  My patients have been thankful for the additional information”.  Another counselor 
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shared how AGG results had significantly altered their patient’s choices about pre-implantation 
genetic diagnosis. 
In order to extrapolate patient demand, counselors were asked if patients had ever asked 
about additional testing (such as AGG analysis) to help refine their risk for expansion in the 
FMR1 gene.  Only 5% of counselors reported patients asking about their additional testing 
options.  Not surprisingly, those counselors reported seeing almost three times as many patients 
as other counselors taking this survey.  
4.1.4 Barriers to Offering/Ordering AGG Testing 
Going into this study, the investigators were under the impression counselors were not 
commonly integrating AGG analysis into their clinical practice conceivably due to limited 
knowledge, lack of perceived importance in care, and concern for cost burden to patients.  As 
anticipated, the majority of counselors (68%) desired more education before they would feel 
knowledgeable enough to discuss this test with their patients.  This is compounded by 40% of 
counselors who reported either not knowing this testing was available or not knowing how to go 
about requesting it.   
Two-thirds of counselors were concerned about insurance coverage and/or the additional 
cost this testing would add for their patient.  Furthermore, although not specifically addressed in 
the survey, a likely inhibitor of testing utilization was laboratory contracts limiting access to 
specific laboratories.  As an example, in the additional comments field of the survey, one 
counselor explained his/her struggle to convince a laboratory administrator to allow the test to be 
sent to the appropriate testing facility.  In this particular situation, the institution anticipated very 
little Medicaid reimbursement and the counselor had difficulty justifying how results would 
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influence the patient’s decision making.  Another counselor went on to say, “In cases where I 
have offered [AGG analysis] to patients, I have felt that it will alter the management of their 
current/future pregnancy… If a patient isn't interested in prenatal diagnosis regardless, and is 
aware of the risks, I wouldn't see AGG testing as being helpful for management”.  Some of the 
Canadian NSGC members shared comments, such as “Government guidelines require that we 
use local labs before sending away to further labs unless there is a clear advantage to testing in 
other lab” and “Working in a publically funded healthcare system, I believe we have to think 
carefully and be very responsible when it comes to deciding which tests are most useful. You 
shouldn't just offer a test because it is available!” 
Surprisingly to the investigators, almost all counselors (91%) felt this testing was relevant 
for their patients with an FMR1 intermediate or premutation allele.  However, one-third of 
counselors felt information gained from AGG analysis added further complexity to FMR1 
genetic counseling without actually changing patient decision making.  A few counselors 
confirmed these sentiments in the comments section, making statements like “Most of my 
population would progress to prenatal diagnosis if they were premutation carriers, regardless of 
AGG analysis.  I'm sure if I worked with a population that was less inclined to have CVS or 
amnio this answer would be different.”  Another counselor said in regards to prenatal diagnosis, 
“I don't think these test results are going to change their choice.  Whether the risk for Fragile X is 
20%, 2%, or 0.5%, I think they would still choose to test and find out for sure.”  Taking the 
opposite stance, one counselor commented that she has a Fragile X premutation allele and would 
want AGG analysis offered to her.  She went on to say that AGG analysis “does increase the 
complexity of counseling but I feel the patient has a right to know and make the decision for 
themselves.” 
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Researchers were interested to determine the impact of AGG knowledge on each of the 
perceived barriers.  As anticipated, counselors who considered themselves less knowledgeable 
about AGG analysis desired more education and/or did not know this testing was available.  
Counselors’ level of knowledge was not a significant predictor for concerns regarding insurance, 
complexity, or irrelevance. 
Researchers further sought to determine if barriers differed among those who have 
offered AGG testing in the past as compared to those who have not.  As expected, counselors 
who have offered testing in the past were less likely to select “I need more education before I 
would feel knowledgeable enough to discuss this with my patients” and “I didn’t know this 
testing was available and/or didn’t know how to request testing”.  Counselors past use of AGG 
testing was not a significant predictor for concerns regarding insurance, complexity, or 
irrelevance. 
4.1.5 Future Use of AGG Analysis 
Researchers were interested to understand when AGG analysis is most likely to be utilized by 
genetic counselors.  The majority of counselors (77%) reported being “more likely” to utilize 
AGG analysis in the presence of a family history consistent with possible Fragile X syndrome, 
Fragile X-associated Tremor/Ataxia syndrome, or Fragile X-associated Primary Ovarian 
Insufficiency.  A few genetic counselors added additional comments to explain that if someone 
has a family history of Fragile X syndrome, then they would be less likely to utilize AGG 
analysis because they already know that the allele can expand to a full mutation. 
Counselors were further asked if there were certain CGG repeat ranges that would make 
them more likely to discuss the option of AGG testing in the future. Respondents were able to 
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mark all repeat ranges that applied.  Sixty-seven counselors (19%) did not plan to discuss this 
testing with their patients.  Of the remaining counselors, about half would discuss AGG testing 
with someone with an intermediate allele (45-54 CGG repeats).  While AGG analysis has been 
marketed as appropriate for known Fragile X carriers with 45-90 repeats, the smallest 
premutation to expand to a full mutation within a single generation is still 56 repeats (Fernandez-
Carvajal et al., 2009). 
  Interestingly, over 65% of counselors would discuss AGG testing with a premutation 
allele carrier with 55-69 CGG repeats.  In addition, the majority of counselors (60%) would 
discuss this testing option with individuals with 70 or higher CGG repeats.  This makes sense, as 
AGG interruptions seem to have the greatest influence in risk prediction for alleles with 70-80 
CGG repeats.  In this repeat range, difference in risk varies by ~60% depending on number of 
AGGs present (Yrigollen et al., 2012).  Finally, 20% of counselors selected all CGG repeat 
ranges (from an intermediate allele with 45 CGG repeats up to a premutation allele with 70 or 
more CGG repeats).  This is likely implying they would discuss AGG testing with an FMR1 
carrier regardless of repeat length.   
Researchers were interested to determine the impact of AGG knowledge on likelihood for 
discussion based on specific repeat ranges.  Counselors with greater knowledge of AGG analysis 
were significantly more likely to discuss this additional testing with a premutation allele carrier 
with 60-69 CGG repeats.  However, knowledge did not seem to influence the likelihood of 
discussion for other repeat ranges.  One counselor outlined their testing strategy stating, “I have 
typically offered it to anyone with a CGG repeat between 55 and 70. Of course, if the family 
history is positive for FX syndrome, I counsel that there is a risk for expansion since it has 
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obviously expanded in other individuals. For the intermediate range, I offer it but emphasize that 
expansion to a full mutation has not been identified in a case yet”. 
Another portion of the survey was designed to capture whether or not counselors planned 
to use AGG analysis differently in the future.  While only 19% of respondents report offering 
AGG analysis to patients in the past, the vast majority of counselors surveyed (87%) say they 
would consider offering AGG analysis in the future.  This willingness to consider offering AGG 
analysis in the future, emphasizes that a lack of perceived importance is not a factor hindering 
genetic counselors in their integration of AGG analysis into clinical practice as previously 
hypothesized. 
4.1.6 Establishment of Formal Guidelines 
There was a divide amongst genetic counselors participating in this survey, with just under half 
believing that informing patients about the option of AGG analysis should be the standard of 
care for genetics service providers.  Counselors rating themselves with a higher level of 
knowledge about AGG analysis were more likely to believe informing patients should be the 
standard of care.  One counselor emphasized in the comments section that their clinic is not 
typically offering AGG analysis until testing becomes the “gold standard” or a recommendation 
of a governing organization.  This counselor explained that at this point, it has been too difficult 
to obtain insurance coverage by medical necessity.  
At present, there are no formal testing guidelines to direct genetic counselors when to 
offer AGG analysis to refine risk for expansion.  As hypothesized, this study found a high level 
of desire for the establishment of these guidelines by a governing organization.  A strong 
majority of counselors (90%) felt formal guidelines should be established for the purpose of 
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identifying who should be offered AGG analysis.  Amongst these individuals, many believed 
either the National Society of Genetic Counselors (NSGC) or the American College of Medical 
Genetics (ACMG) should be the organization responsible for their establishment.  Some 
counselors also mentioned preferences for the American Congress of Obstetrics and 
Gynecologists (ACOG) and/or The American Academy of Pediatrics (AAP). 
4.2 DISCUSSION OF INTERNATIONAL RESULTS 
4.2.1 Demographics 
Two hundred and seventy-one ASGC members and approximately three hundred members of 
AGNC were invited to participate in this research study.  Of these, sixteen ASGC members (6%) 
and twelve AGNC members (4%) took part in the survey.  Of the AGNC respondents, one was a 
genetic nurse and the rest were genetic counselors.  It is problematic to draw any assumptions of 
the larger organizations based off these small response rates.  In this discussion, the researchers 
hope to shed light on the thoughts and opinions of the survey respondents recognizing that these 
may be unique to these individuals. 
The majority of respondents (64%) had been practicing for five or more years. 
Experience ranged from 6 months to 30 years, with an average of 8 years.  Similar to NSGC 
respondents, the majority (68%) of counselors reported specializing in prenatal genetics.  Many 
of these individuals reported specializing in additional areas of genetics as well.  Unlike the 
distribution among NSGC respondents, the bulk of international counselors reported specializing 
in adult genetics (79%).  A handful of respondents reported specializing in areas such as X-
linked disorders, pre-implantation genetic diagnosis, and learning disabilities. 
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4.2.2 Knowledge of AGG Analysis 
Only three counselors (11%) considered themselves very knowledgeable, whereas most 
counselors (74%) reported themselves as not at all knowledgeable.  Overall, international 
respondents were significantly less knowledgeable about AGG analysis than NSGC respondents.  
Researchers anticipated this as testing is not clinically available abroad.  Amongst the seven 
counselors with at least some degree of knowledge, education about AGG analysis was obtained 
by reading peer-reviewed articles on the studies performed to date, attending 
lectures/presentations on AGG analysis and/or discussing it with either a company that performs 
the testing or their own local laboratory.  
4.2.3 FMR1 Patient Experience 
All of the international counselors surveyed counsel patients.  Further, the majority (89%) have 
counseled a patient with an FMR1 intermediate or premutation allele.  Polling these individuals, 
they have on average each counseled ~5.7 patients with an FMR1 intermediate or premutation 
allele over the past 3 years, ranging from 0 to 20. The median number of patients counseled with 
an FMR1 intermediate or premutation allele over the past 3 years was 3. 
Counselors were further asked how often they discuss the role of AGG analysis when 
counseling patients with an FMR1 intermediate or premutation allele.  Two respondents felt this 
question was not applicable to them, likely because they do not counsel patients for this 
indication.  Of the remaining counselors, the majority (81%) “never” discussed the role of AGG 
analysis.  Few (19%) report discussing the role of AGG analysis “occasionally” or “often”, and 
no one selected “always”.  Regardless of whether or not counselors chose to discuss AGG 
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analysis in session, none of them had offered clinical AGG testing and only two counselors (9%) 
had offered AGG testing as part of a research study.  
In order to extrapolate patient demand, counselors were asked if patients had ever asked 
about additional testing (such as AGG analysis) to help refine their risk for expansion in the 
FMR1 gene.  Only 1 counselor (4%) reported patients asking about their additional testing 
options. 
4.2.4 Barriers to Offering/Ordering AGG Testing 
Going into this study the researchers were not aware of any international counselors that had 
integrated AGG analysis into their clinical practice.  This can likely be largely attributed to the 
lack of available clinical testing internationally.  As projected, the majority of counselors (87%) 
either didn’t know this testing was available or didn’t know how to request it.  In addition, the 
majority (83%) desired more education before they would feel knowledgeable enough to discuss 
this with their patients.  Most counselors did not report insurance concerns, complexity, or 
irrelevance as obstacles preventing them from offering/ordering AGG testing. 
Perceived barriers to offering/ordering AGG testing were stratified to determine if 
perceptions differed among international versus NSGC respondents.  International counselors 
were significantly more likely to select “I didn’t know this testing was available and/or didn’t 
know how to request testing”.  In addition, international counselors were statistically less likely 
to mark down concerns about insurance coverage.  One reason international respondents do not 
seem to have the same concerns regarding insurance coverage that NSGC respondents do is 
likely due to the differing healthcare systems in both the UK and Australasia as compared to the 
United States.  Counselors’ need for education, concerns about complexity and feelings of 
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irrelevance were not significantly influenced by affiliation with the NSGC or an international 
organization. 
4.2.5 Future Use of AGG Analysis 
Researchers were interested to understand when AGG analysis is most likely to be utilized by 
genetic counselors.  The majority of counselors (74%) reported being “more likely” to utilize 
AGG analysis in the presence of a family history consistent with possible Fragile X syndrome, 
Fragile X-associated Tremor/Ataxia syndrome, or Fragile X-associated Primary Ovarian 
Insufficiency.   
Another portion of the survey was designed to capture whether or not counselors planned 
to use AGG analysis differently in the future.  Similar to NSGC respondents, the majority of 
counselors surveyed (91%) said they would consider offering AGG analysis in the future.  This 
willingness to consider offering AGG analysis in the future emphasizes that a lack of perceived 
importance is not a factor hindering genetic counselors in their integration of AGG analysis into 
clinical practice as previously hypothesized by this study. 
4.2.6 Establishment of Formal Guidelines 
Unlike NSGC respondents, the majority of international counselors (73%) did not believe 
informing patients about the option of AGG analysis should be the standard of care for genetics 
service providers.  This approached but did not reach statistical significance.  However, this 
study did find a high level of desire for the establishment of formal testing guidelines by a 
governing organization.  This was true for both NSGC respondents and the majority (91%) of 
international counselors.  While some respondents thought either the American College of 
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Medical Genetics (ACMG) or the National Society of Genetic Counselors (NSGC) should be the 
organization responsible for establishing these guidelines, others specified organizations such as 
the Human Genetics Society of Australasia (HGSA), the British Society for Genetic Medicine 
(BSGM), and the Association of Genetic Nurses and Counsellors (AGNC). 
4.3 STUDY LIMITATIONS 
This exploratory study aimed to better understand genetic counselors’ knowledge, utilization, 
and attitudes towards the clinical utility of AGG analysis for their patients.  Some aspects of the 
study design must be noted.  First, self-selection bias must be acknowledged as participants 
opted to take part in the survey.  While it was not feasible to ascertain reasons for not 
participating, researchers noticed that those most likely to respond were prenatal genetic 
counselors and/or those with relevant FMR1 patient experience.  Due to the low response rates, 
particularly among the international respondents, it is problematic to draw any generalizations of 
the larger organizations.  Rather, these findings should be used to shed light on the thoughts and 
opinions of the survey respondents recognizing that these may be unique to these individuals.  It 
is possible that participants with stronger viewpoints took part in this survey.  Another aspect of 
the study design that limited interpretation was the requirement to answer each survey question 
in order to proceed.  This was problematic for counselors with little to no knowledge of AGG 
analysis.  At the end of the survey, several counselors commented they wanted to answer “I don’t 
know” or “unsure” but were not given this option.  This likely led some counselors to exit the 
survey before finishing and forced others to provide answers that did not reflect their true 
responses.   
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4.4 PRACTICE IMPLICATIONS 
At present, there are no formal testing guidelines to direct genetic counselors when to offer AGG 
analysis to refine risk for expansion.  This study found a high level of desire for the 
establishment of these guidelines for the purpose of identifying who should be offered AGG 
analysis.  Many believed either the National Society of Genetic Counselors (NSGC) or the 
American College of Medical Genetics (ACMG) should be the organization responsible for their 
establishment.  Information gathered from this study will be of benefit to the genetic counseling 
profession and may impact the utilization of AGG analysis in the future. 
4.5 RESEARCH RECOMMENDATIONS  
Future studies could provide more qualitative analysis through semi-structured interviews. This 
could include interviewing both genetic counselors who offer and do not offer AGG analysis.  
Either through individual interviews or focus groups this type of future research could help 
define what the standard of care will become.  Future research is also needed to explore patients’ 
perceptions of the benefits and limitations of AGG analysis in the both the short- and long-term. 
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5.0  CONCLUSION 
This research was an effort to better understand genetic counselors’ knowledge, utilization, and 
attitudes towards the clinical utility of AGG analysis for their patients.  Almost all survey 
respondents, in the United States and internationally, reported experience with patients with 
FMR1 intermediate or premutation alleles.  However, no international respondents and only a 
minority of NSGC members reported actually offering AGG analysis to their patients.  Going 
into this study, the investigators were under the impression counselors were not commonly 
integrating AGG analysis into their clinical practice.  The hypothesis for this study was that 
genetic counselors were reserved in their uptake due to limited knowledge, lack of perceived 
importance in care, and concern for cost burden to patients.  
As anticipated, the majority of counselors desired more education before they would feel 
knowledgeable enough to discuss this test with their patients.  This is compounded by the fact 
that 40% of NSGC counselors, and an even greater percentage of international counselors, 
reported either not knowing this testing was available or not knowing how to go about requesting 
it.  NSGC counselors were significantly more knowledgeable about AGG analysis as compared 
to their international counterparts.  This is likely due to the absence of the clinical availability of 
this testing abroad.  Counselors who considered themselves to be more knowledgeable about 
AGG analysis were significantly more likely to discuss this topic with patients during 
counseling.  
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 Surprisingly to the investigators, almost all counselors felt AGG analysis was relevant for 
their patients with an FMR1 intermediate or premutation allele.  Researchers had postulated that 
information gained from AGG analysis added further complexity to FMR1 genetic counseling 
without actually changing patient decision making.  It was thought that this lack of perceived 
importance might have influenced the low uptake of this testing methodology.  In actuality, only 
one-third of NSGC counselors felt this way.  In addition, knowledge about AGG analysis was 
not a significant predictor for how counselors would respond to this question. 
While only 19% of NSGC respondents report offering AGG analysis to patients in the 
past, the vast majority of NSGC and international counselors surveyed say they would consider 
offering AGG analysis in the future.  This willingness to consider offering this testing in the 
future, further emphasizes that a lack of perceived importance is not a factor hindering genetic 
counselors in their integration of AGG analysis into clinical practice as previously hypothesized.  
This was reiterated by data showing NSGC counselors with a higher level of AGG knowledge 
were more likely to believe informing patients should be the standard of care. 
As expected by the investigators, two-thirds of NSGC counselors were concerned about 
insurance coverage and/or the additional cost this testing would add for their patient.  
International respondents were less likely to report this as a perceived barrier to ordering/offering 
testing.  
At present, there are no formal testing guidelines to direct genetic counselors when to 
offer AGG analysis to refine risk for expansion.  As hypothesized, this study found a high level 
of desire for the establishment of these guidelines by a governing organization.  A strong 
majority of counselors felt formal guidelines should be established for the purpose of identifying 
who should be offered AGG analysis.  Amongst these individuals, many believed either the 
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National Society of Genetic Counselors (NSGC) or the American College of Medical Genetics 
(ACMG) should be the organization responsible for their establishment.   
 Information gathered from this study will be of benefit to the genetic counseling 
profession and may impact the utilization of genetic testing methodologies in the future. 
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APPENDIX B: RECRUITMENT MATERIALS 
B.1 RECRUITMENT BROCHURE 
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B.2 RECRUITMENT E-MAILS 
B.2.1 NSGC Recruitment E-mail 
Dear Genetic Counselor, 
  
I am second year genetic counseling student at the University of Pittsburgh.  I am collaborating 
on a research study, with some of the leaders in the Fragile X field, to explore genetic 
counselors’ perceptions and utilization of additional testing to refine the risk of expansion in the 
FMR1 gene.  
  
It is our hope that information gathered from this study will be of benefit to the genetic 
counseling profession and impact the utilization of genetic testing methodologies in the future.  
Your insight would be valuable, even if you do not regularly see patients with mutations in their 
FMR1 gene.  
  
If you agree to participate, you will be asked to complete a brief, online survey. Completion of 
the anonymous survey should take no longer than 10 minutes. Simply click on the link below, or 
cut and paste the entire URL into your browser to access the survey: 
  
https://www.surveymonkey.com/s/FragileXtesting 
  
We would appreciate your response by Friday, November 8, 2013. 
 
If you have comments, concerns, or questions about this research study, feel free to contact me. 
  
Sincerely, 
 
Lauren H. Brown, BA 
Genetic Counseling Intern 
University of Pittsburgh 
(360) 606-4706 
Lhb11@pitt.edu 
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B.2.2 ASGC Recruitment E-mail 
Dear ASGC members, 
 
A Master of Genetic Counselling student in the US is conducting a survey exploring genetic 
counsellors' perceptions and utilization of AGG analysis to refine the risk of expansion in the 
FMR1 gene. 
 
The research team is keen to include Australasian genetic counsellors in the survey and hopes 
that information gathered from this study will be of benefit to the genetic counselling profession 
and impact the utilization of genetic testing methodologies in the future.  Your insight would be 
valuable, even if you do not regularly see patients with expansions in their FMR1 gene. 
 
If you agree to participate, you will be asked to complete a brief, online survey. Completion of 
the anonymous survey should take no longer than 10 minutes. Simply click on the link below, or 
cut and paste the entire URL into your browser to access the survey: 
 
https://www.surveymonkey.com/s/FragileX-ASGC 
 
We would appreciate your response by Friday, December 20, 2013. 
 
If you have comments, concerns, or questions about this research study, feel free to contact 
Lauren H. Brown, Genetic Counselling Student at the University of Pittsburgh, Lhb11@pitt.edu. 
 
The study team includes: 
 
Liane J. Abrams, MS, LGC (National Fragile X Foundation) 
Alison D. Archibald, PhD., GDipGenetCouns. (Victorian Clinical Genetics Services) 
Robin L. Bennett, MS, CGC, D. Sc. Hon. (University of Washington Medical Center) 
Lauren H. Brown, BA (University of Pittsburgh) 
Amy Cronister, MS (Integrated Genetics) 
Brenda Finucane, MS, CGC (Geisinger Health System) 
Allyn McConkie-Rosell,  Ph.D. CGC (Duke University Medical Center) 
 
Kind regards, 
 
  
Lauren 
 
Lauren H. Brown, BA 
Genetic Counseling Intern 
University of Pittsburgh 
(360) 606-4706 
Lhb11@pitt.edu 
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B.2.3 AGNC Recruitment E-mail 
Dear AGNC members, 
 
I am a master of Genetic Counselling student in the US conducting a survey exploring genetic 
counsellors' perceptions and utilization of AGG analysis to refine the risk of expansion in the 
FMR1 gene. 
 
The research team is keen to include genetic professionals from the UK in the survey and hopes 
that information gathered from this study will be of benefit to the genetic counselling profession 
and impact the utilization of genetic testing methodologies in the future.  Your insight would be 
valuable, even if you do not regularly see patients with expansions in their FMR1 gene. 
 
If you agree to participate, you will be asked to complete a brief, online survey. Completion of 
the anonymous survey should take no longer than 10 minutes. Simply click on the link below, or 
cut and paste the entire URL into your browser to access the survey: 
 
https://www.surveymonkey.com/s/FragileX-UK 
 
We would appreciate your response by Friday, November 8, 2013. 
 
If you have comments, concerns, or questions about this research study, feel free to contact me. 
 
The study team includes: 
 
Liane J. Abrams, MS, LGC (National Fragile X Foundation) 
Alison D. Archibald, PhD., GDipGenetCouns. (Victorian Clinical Genetics Services) 
Robin L. Bennett, MS, CGC, D. Sc. Hon. (University of Washington Medical Center) 
Lauren H. Brown, BA (University of Pittsburgh) 
Amy Cronister, MS (Integrated Genetics) 
Brenda Finucane, MS, CGC (Geisinger Health System) 
Allyn McConkie-Rosell,  Ph.D. CGC (Duke University Medical Center) 
 
Kind regards, 
  
 
Lauren 
 
Lauren H. Brown, BA 
Genetic Counseling Intern 
University of Pittsburgh 
(360) 606-4706 
Lhb11@pitt.edu 
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APPENDIX C: SURVEY FIRST DRAFT 
1. Number of years in practice as a genetic counselor:  __0-5   __6-10  __10-15  __>15 
 
2. Do you see patients?   __Yes __No 
 
3. Specialty area(s):  ___Prenatal ___Pediatric ___Cancer ___Adults genetics ___Other:_____  
 
4. How many patients have you counseled who had a FMR1 mutation / intermediate allele over 
the past year?       ___0       ___1-5           ___6-10          ___11-20           ___>20 
 
5. On a scale of 1 to 5, with 1 being not at all knowledgeable and 5 being very knowledgeable, 
how would you rate your knowledge about the value of analyzing AGG interruptions in women 
with FMR1 intermediate or small premutation alleles?  _____ 
 
If you rated yourself 2 or higher, please indicate how you learned and were educated 
about AGG analysis (Mark all that apply) 
___ Attended a lecture on AGG analysis 
___ Read peer review articles on the studies performed to date 
___ Discussed it with a company or institutions that performs the testing 
___ Other (Please Clarify): ________________ 
 
6. When counseling patients with FMR1 intermediate or premutation alleles, how often do you 
discuss the role of AGG interruptions?  
___Never ____Rarely ___Sometimes ___Almost always ___Always    
7. When counseling patients with FMR1 intermediate or premutation alleles, how often do you 
offer follow-up AGG testing? 
___Never ____Rarely ___Sometimes ___Almost always ___Always     
8. If you have offered AGG testing, please indicate why testing was offered (Mark all that apply)   
___ For further clarification of risk of expansion in a preconception or pregnant woman 
with an intermediate allele (45-54 CGG repeats) 
___ For further clarification of risk of expansion in a preconception or pregnant woman 
with a premutation with 55-59 CGG repeats 
___ For further clarification of risk of expansion in a preconception or pregnant woman 
with a premutation with 60-64 CGG repeats 
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___ For further clarification of risk of expansion in a preconception or pregnant woman 
with a premutation with 65-69 CGG repeats 
___ For further clarification of risk of expansion in a preconception or pregnant woman 
with a premutation with 70 or higher CGG repeats 
___ As part of a family study 
___ As part of a research study 
___To assist the patient in making a decision regarding prenatal diagnosis  
___ To assist the patient in making decisions about family planning 
___ Because it is standard of care 
___ Because the patient requested AGG analysis 
___ Other (Please Clarify ) ____________________________________________ 
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APPENDIX D: SURVEY FINAL DRAFT 
1. This survey is part of a research study to explore genetic counselors’ perceptions and 
utilization of AGG analysis to refine the risk of expansion in the FMR1 gene.  If you 
agree to participate, you will be asked to complete a brief, online survey. Completion of 
the survey should take no longer than 10 minutes.  
 
There is minimal risk involved in this study. All results generated through the electronic 
survey will be collected anonymously. Given the nature of the topic, it is possible that 
some questions may cause distress, as some individuals may feel uncomfortable thinking 
about the ethical implications of deciding whether or not to offer AGG testing to patients. 
Your participation in this study is completely voluntary and you may choose to exit the 
survey at any point.  
 
There are no costs to you for participating in this study, and you will receive no direct 
benefit from participating. Information gathered from this study will be of benefit to the 
genetic counseling profession and may impact the utilization of genetic testing 
methodologies in the future.  
 
If you have comments, concerns, or questions about this research study, you may contact 
Lauren Brown, BA by email at Lhb11@pitt.edu.  
 
If you have questions about your rights as a research participant, please contact the 
Human Subjects Protection Advocate at the University of Pittsburgh IRB Office, (866) 
212-2668. 
 
I have read the above information and agree to participate in this research study.  
 
___I accept the conditions       ___I do not accept the conditions 
 
2. Approximately how many years have you been in practice as a genetic counselor?      ___ 
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3. Specialty area(s) (Mark all that apply): ___Prenatal ___Pediatrics ___Cancer ___Adult 
genetics     ___Research/Laboratory         ___Other (Please Clarify) _________________ 
 
4. Do you counsel patients?   __Yes __No 
 
5. Do you primarily work in the United States?    __Yes         __No   
a. If no, in which country do you primarily work? __________ 
 
6. Have you ever counseled a patient with an FMR1 intermediate or premutation allele?  
__Yes         __No   
a. If yes, approximately how many patients have you counseled with an FMR1 
intermediate or premutation allele within the past 3 years?  ____ 
 
7. On a scale of 1 to 4, with 1 being not at all knowledgeable and 4 being very 
knowledgeable, how familiar are you with the notion of analyzing AGG interruptions in 
women with an FMR1 intermediate or premutation allele?  _____ 
 
8. If you rated yourself 2 or higher, please indicate how you became educated about AGG 
analysis. (Mark all that apply) 
___ Attended a lecture/presentation on AGG analysis 
___ Viewed or participated in a webinar on AGG analysis 
___ Read peer-reviewed articles on the studies performed to date 
___ Read promotional materials from a company or institution that performs the testing 
___ Discussed it with a company or institution that performs the testing 
 
9. Has a patient ever asked you about additional testing (such as AGG analysis) to help 
refine their risk of expansion in the FMR1 gene?  __Yes     __No 
 
10. When counseling patients with an FMR1 intermediate or premutation allele, how often 
do you discuss the role of AGG analysis to refine the risk of expansion in the FMR1 
gene?    ___Never      ___Occasionally      ___Often       ___Always     ___N/A 
 
11. If you have offered AGG testing, please indicate why testing was offered. (Mark all that 
apply)  
___ As part of a research study 
___ Because it is standard of care 
___ Because the patient requested AGG analysis 
___ To assist the pregnant patient in making a decision regarding prenatal diagnosis  
___ To assist the patient in making decisions about family planning 
___ N/A – I have not offered this testing 
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12. Would you be more or less likely to utilize this testing methodology in the presence of 
family history consistent with possible Fragile X Syndrome, Fragile X-associated 
Tremor/Ataxia Syndrome, or Fragile X-associated Primary Ovarian Insufficiency? 
__More likely __Less likely 
 
13. In the future, for which CGG repeat range would you be most likely to discuss the option 
of AGG testing for further clarification of risk of expansion? (Mark all that apply) 
___ An intermediate allele (45-54 CGG repeats) 
___ A premutation with 55-59 CGG repeats 
___ A premutation with 60-64 CGG repeats 
___ A premutation with 65-69 CGG repeats 
___ A premutation with 70 or higher CGG repeats 
___ None of the above, I do not plan to discuss this testing option with my patients 
 
14. With which category do you most closely identify? 
___ I have offered AGG analysis to patients in the past and will consider doing so again 
in the future 
___ I have offered AGG analysis to patients in the past, however, I do not plan to offer 
this testing in the future 
___ I have not offered AGG analysis to patients in the past, but would consider doing so 
in the future 
___ I have not offered AGG analysis to patients in the past, and I do not plan to offer this 
testing in the future   
 
15. Please answer the following true/false questions to help clarify what prevents you from 
offering/ordering AGG testing (if anything).  
True or False I didn’t know this testing was available and/or didn’t know how to 
request testing 
 
True or False I need more education before I would feel knowledgeable enough to 
discuss this with my patients 
 
True or False I am concerned about insurance coverage and/or the additional cost this 
testing would add for my patient 
 
True or False I feel this information adds further complexity to FMR1 genetic 
counseling without actually changing patient decision-making 
 
True or False I feel this testing is not relevant for my patients with an FMR1 
intermediate or premutation allele 
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16. For patients with whom you discuss the role of AGG analysis to refine the risk of 
expansion in the FMR1 gene, approximately what percentage chooses to have the AGG 
analysis performed?      ___ % ___ N/A – I do not discuss this 
 
17. Should informing patients about the option of AGG analysis be the standard of care for 
genetics service providers?       __Yes __No 
 
18. Do you believe formal guidelines should be established for the purpose of identifying 
who should be offered AGG analysis?     __Yes __No    
 
19. If Yes, what organization(s) do you think should establish the guidelines? (Mark all that 
apply):   
___ National Society of Genetic Counselors (NSGC)       
___ American College of Medical Genetics (ACMG)      
___ American Congress of Obstetrics and Gynecologists (ACOG)     
___ American Academy of Pediatrics (AAP)       
___ Other (Please Clarify) ________________________________ 
 
20. Any additional comments about why you do/do not provide AGG analysis to help refine 
FMR1 gene expansion risk? 
 
Comments_________________________________________________________ 
 
 
Thank you very much for completing this survey. Your feedback is greatly appreciated. 
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APPENDIX E: ADDITIONAL TABLES 
Table 16. NSGC—Perceived Barriers Based on Familiarity II: Insurance 
I am concerned about insurance coverage and/or the 
additional cost this testing would add for my patient 
 TRUE FALSE Knowledge Level 
1 or 2 135 58 
Knowledge Level 
3 or 4 97 60 
Two-tailed Fisher’s exact test: p-value = 0.11 
 
Table 17. NSGC—Perceived Barriers Based on Familiarity II: Complexity 
 
Two-tailed Fisher’s exact test: p-value = 0.82 
 
Table 18. NSGC—Perceived Barriers Based on Familiarity II: Irrelevance 
I feel this testing is not relevant for my patients with an 
FMR1 intermediate or premutation allele 
 TRUE FALSE Knowledge Level 
1 or 2 20 173 
Knowledge Level 
3 or 4 12 145 
Two-tailed Fisher’s exact test: p-value = 0.46 
I feel this information adds further complexity to FMR1 
genetic counseling without actually changing patient 
decision making 
 TRUE FALSE Knowledge Level 
1 or 2 65 128 
Knowledge Level 
3 or 4 51 106 
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Table 19. NSGC—Perceived Barriers Based on Past Use: Insurance 
I am concerned about insurance coverage and/or the 
additional cost this testing would add for my patient 
 TRUE FALSE Have offered AGG analysis to 
patients in the past 41 27 
Have NOT offered AGG 
analysis to patients in the past 191 91 
Two-tailed Fisher’s exact test: p-value = 0.26 
 
Table 20. NSGC—Perceived Barriers Based on Past Use: Complexity 
I feel this information adds further complexity to FMR1 
genetic counseling without actually changing patient 
decision making 
 TRUE FALSE Have offered AGG analysis to 
patients in the past 21 47 
Have NOT offered AGG 
analysis to patients in the past 95 187 
Two-tailed Fisher’s exact test: p-value = 0.67 
 
Table 21. NSGC—Perceived Barriers Based on Past Use: Irrelevance 
I feel this testing is not relevant for my patients with an 
FMR1 intermediate or premutation allele 
 TRUE FALSE Have offered AGG analysis to 
patients in the past 6 62 
Have NOT offered AGG 
analysis to patients in the past 26 256 
Two-tailed Fisher’s exact test: p-value = 1 
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Table 22. NSGC—AGG Discussion Based on Familiarity: 45-54 repeats 
An intermediate allele (45-54 CGG repeats) 
 Yes No Knowledge Level 
1 or 2 70 76 
Knowledge Level 
3 or 4 64 81 
Two-tailed Fisher’s exact test: p-value = 0.56 
 
Table 23. NSGC—AGG Discussion Based on Familiarity: 55-59 repeats 
A premutation with 55-59 CGG repeats 
 Yes No Knowledge Level 
1 or 2 97 49 
Knowledge Level 
3 or 4 109 36 
Two-tailed Fisher’s exact test: p-value = 0.12 
 
Table 24. NSGC—AGG Discussion Based on Familiarity: 70+ repeats 
A premutation with 70 or higher CGG repeats 
 Yes No Knowledge Level 
1 or 2 89 57 
Knowledge Level 
3 or 4 85 60 
Two-tailed Fisher’s exact test: p-value = 0.72 
 
Table 25. Perceived Barriers for International vs. NSGC Respondents: Education 
I need more education before I would feel knowledgeable 
enough to discuss this with my patients 
 TRUE FALSE 
International 19 4 
NSGC 237 113 
One-tailed Fisher’s exact test: p-value = 0.1 
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Table 26. Perceived Barriers for International vs. NSGC Respondents: Complexity 
I feel this information adds further complexity to FMR1 
genetic counseling without actually changing patient 
decision making 
 TRUE FALSE 
International 7 16 
NSGC 116 234 
Two-tailed Fisher’s exact test: p-value = 0.82 
 
Table 27. Perceived Barriers for International vs. NSGC Respondents: Irrelevance 
I feel this testing is not relevant for my patients with an 
FMR1 intermediate or premutation allele 
 TRUE FALSE 
International 3 20 
NSGC 32 318 
Two-tailed Fisher’s exact test: p-value = 0.71 
 
Table 28. Standard of Care for International vs. NSGC Respondents 
Should informing patients about the option of AGG 
analysis be the standard of care for genetics service 
providers? 
 YES NO 
International 6 16 
NSGC 155 193 
One-tailed Fisher’s exact test: p-value = 0.08 
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